Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS May Expand Opioid Abuse Measures To Other Classes In Part D, Insurers Told

This article was originally published in The Pink Sheet Daily

Executive Summary

At the AHIP Medicare conference, CMS official Andrea Bendewald presents preliminary data indicating the agency’s measures for preventing opioid abuse are having the desired effect. She also discusses formulary edits in the upcoming 2014 Part D plans aimed at curtailing overuse of opioids and other “high risk medications.”

You may also be interested in...



Insurer Seeks To Recover ‘Illegal’ Daraprim Overcharges Due To Obstruction Of Generics

Proposed class action lawsuit by Blue Cross Blue Shield of Minnesota against Vyera Pharmaceuticals could set a precedent for other health insurer actions against manufacturers.

Tie Goes To The Nominee: Becerra Heads To Senate Floor

Without Republican support, Biden’s HHS nominee couldn’t get a majority in the Finance Committee, but that shouldn’t imperil his bid to become secretary of Health and Human Services.

AstraZeneca/FibroGen’s Roxadustat Comparison To ESAs In Anemia May By Clarified At FDA Advisory Cmte.

Payers would welcome any additional clarity provided by advisory panel review, given the perception, expressed in a recent ICER report, that the evidence is insufficient to determine whether the new drug is safer or more effective than erythropoiesis-stimulating agents.

Topics

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel